Literature DB >> 11230360

Potentiation of bradykinin by angiotensin-(1-7) on arterioles of spontaneously hypertensive rats studied in vivo.

L Fernandes1, Z B Fortes, D Nigro, R C Tostes, R A Santos, M H Catelli De Carvalho.   

Abstract

In the present study, we investigated the potentiating effect of angiotensin-(1-7) [Ang-(1-7)] on bradykinin (BK)-induced vasodilation in the mesenteric vascular bed of anesthetized spontaneously hypertensive rats using intravital microscopy. Topical application of BK and Ang-(1-7) induced vasodilation in mesenteric arterioles. The BK-induced effect, but not acetylcholine, sodium nitroprusside, or histamine responses, was potentiated in the presence of Ang-(1-7). This interaction was abolished by BK-B(2) and Ang-(1-7) antagonists (HOE 140 and A-779, respectively), a K(+) channel blocker (tetraethylammonium), and cyclooxygenase inhibitors (indomethacin and diclofenac); however, nitric oxide synthase inhibition (Nomega-nitro-L-arginine methyl ester) did not modify the Ang-(1-7)-potentiating activity. Long-term angiotensin-converting enzyme (ACE) inhibition increased BK and Ang-(1-7)-induced vasodilation. The BK potentiation by Ang-(1-7) was preserved after ACE inhibition, Ang II type 1 receptor blockade, or the combination of both treatments. The most striking finding of this study was the unexpected observation that the potentiation of BK vasodilation in spontaneously hypertensive rats treated short- or long-term with ACE inhibitors was reverted by the Ang-(1-7) antagonist A-779. Our results unmasked a key role for an Ang-(1-7)-related mechanism in mediating BK potentiation by ACE inhibitors.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11230360     DOI: 10.1161/01.hyp.37.2.703

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  27 in total

Review 1.  Contribution of angiotensin-(1-7) to cardiovascular physiology and pathology.

Authors:  Carlos M Ferrario
Journal:  Curr Hypertens Rep       Date:  2003-04       Impact factor: 5.369

2.  Advances in the renin angiotensin system focus on angiotensin-converting enzyme 2 and angiotensin-(1-7).

Authors:  Carlos M Ferrario; Sarfaraz Ahmad; Janae Joyner; Jasmina Varagic
Journal:  Adv Pharmacol       Date:  2010

Review 3.  ACE2: more of Ang-(1-7) or less Ang II?

Authors:  Carlos M Ferrario
Journal:  Curr Opin Nephrol Hypertens       Date:  2011-01       Impact factor: 2.894

4.  Angiotensin-(1-7) administration reduces oxidative stress in diabetic bone marrow.

Authors:  N M Mordwinkin; C J Meeks; S S Jadhav; T Espinoza; N Roda; G S diZerega; S G Louie; K E Rodgers
Journal:  Endocrinology       Date:  2012-03-20       Impact factor: 4.736

Review 5.  The renin angiotensin aldosterone system and insulin resistance in humans.

Authors:  Patricia C Underwood; Gail K Adler
Journal:  Curr Hypertens Rep       Date:  2013-02       Impact factor: 5.369

6.  Bradykinin potentiation by ACE inhibitors: a matter of metabolism.

Authors:  Beril Tom; Andreas Dendorfer; René de Vries; Pramod R Saxena; A H Jan Danser
Journal:  Br J Pharmacol       Date:  2002-09       Impact factor: 8.739

7.  Angiotensin-(1-7) inhibits in vitro endothelial cell tube formation in human umbilical vein endothelial cells through the AT(1-7) receptor.

Authors:  Lauren Anton; David C Merrill; Liomar A A Neves; K Bridget Brosnihan
Journal:  Endocrine       Date:  2007-11-15       Impact factor: 3.633

8.  Angiotensin-(1-7) Selectively Induces Relaxation and Modulates Endothelium-Dependent Dilation in Mesenteric Arteries of Salt-Fed Rats.

Authors:  Gábor Raffai; Julian H Lombard
Journal:  J Vasc Res       Date:  2016-09-28       Impact factor: 1.934

Review 9.  The sweeter side of ACE2: physiological evidence for a role in diabetes.

Authors:  Sharell M Bindom; Eric Lazartigues
Journal:  Mol Cell Endocrinol       Date:  2008-10-01       Impact factor: 4.102

Review 10.  New angiotensins.

Authors:  Jasmina Varagic; Aaron J Trask; Jewell A Jessup; Mark C Chappell; Carlos M Ferrario
Journal:  J Mol Med (Berl)       Date:  2008-04-25       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.